XORTX 疗法有180天的时间来恢复纳斯达克最低1美元股价规则或面临除名。 XORTX Therapeutics has 180 days to regain Nasdaq’s $1 minimum share price rule or face delisting.

XORTX治疗公司于2025年10月20日收到一份Nasdaq通知,指出其股份在连续30个营业日低于最低标价门槛后,不再符合1美元的最低标价要求。 XORTX Therapeutics received a Nasdaq notification on October 20, 2025, stating its shares are no longer compliant with the $1.00 minimum bid price requirement after closing below that threshold for 30 consecutive business days. 该公司获准延长180天,现延长至2026年4月13日,以恢复合规。 The company has been granted an 180-day extension, now until April 13, 2026, to regain compliance. 如果股票价格在此期间连续10个营业日达到或超过1美元,Nasdaq将确认遵守规定。 If the share price reaches $1.00 or more for 10 consecutive business days during this period, Nasdaq will confirm compliance. 未能满足这一要求可能导致除名,但向Nasdaq听讯小组提出上诉可能会延误这一结果。 Failure to meet the requirement may lead to delisting, though an appeal to a Nasdaq Hearings Panel could delay that outcome. 公司仍然在TSX风险交易所上市。 The company remains listed on the TSX Venture Exchange. XORTX正在研制肾病治疗方法,并计划探讨解决这种缺陷的所有备选办法。 XORTX is developing therapies for kidney-related conditions and plans to explore all options to resolve the deficiency.